On 11 January 2016, orphan designation (EU/3/15/1604) was granted by the European Commission to Medpace Germany GmbH, Germany, for two allogeneic irradiated pancreatic tumour cell lines (also known as GVAX) for the treatment of pancreatic cancer.
The sponsorship was transferred to Aduro Biotech Holdings, Europe B.V., The Netherlands, in April 2016.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in December 2019 on request of the Sponsor.
Two allogeneic irradiated pancreatic tumour cell lines
|Disease / condition||
Treatment of pancreatic cancer
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
Pivot Park RX 1101
5349 AC Oss
Tel. +31 8 80 12 14 00
Fax +31 2 07 11 81 40
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.